Expression of apoptosis regulators Bcl-2 and Bax in childhood acute lymphoblastic leukemia

References

• Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957–963.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Bc1-2 oncoprotein blocks chemo-therapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151–157.
   PubMed Web of Science ®Google Scholar
• Lotem J, Sachs L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bc1-2 dependent and independent pathways. Cell Growth Differ 1994;5:321–327.
   PubMedGoogle Scholar
• Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bc1-2 oncoprotein in non-Hodgkin’s lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994;5:61–65.
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bc1-2 protein expression in aggressive non-Hodgkin’s lymphoma. Blood 1996;87:265–272.
   PubMed Web of Science ®Google Scholar
• Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bc1-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10: 456–462.
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault J-P, Sabido O, et al. High expression of bc1-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81: 3091–3096.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French—American—British (FAB) co-operative group. Br J Haematol 1976;33: 451–458.
   PubMed Web of Science ®Google Scholar
• Sobol RE, Royston I, LeBien TW, et al. Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood 1985;65:730–735.
   PubMed Web of Science ®Google Scholar
• Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phos-phatase (APAAP) complexes. J Histochem Cytochem 1984; 32:219–227.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Reaman G, Steinherz PG, et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A Children’s Cancer Group Study. Leuk Lymphoma 1996;(24):57–70.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Song CW. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 1993;81:1323–1332.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Steinherz PG, Sather H, et al. CD2 Antigen Expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: A Children’s Cancer Group Study. Blood 1996; 88:4288–4295.
   PubMed Web of Science ®Google Scholar
• Pezella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of Bc1-2 oncogene protein is not specific for t(14:18) chromosomal translocation. Am J Pathol 1990;137:225–232.
   PubMed Web of Science ®Google Scholar
• Krajewski, et al. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471–4478.
   PubMed Web of Science ®Google Scholar
• Rowan RM, Bain BJ, England JM, et al. Immunophenotyping in the diagnosis of acute leukemias. General hematology task force of BCSH. J Clin Pathol 1994;47:777–781.
   Google Scholar
• Buccheri V, Mihalijevic B, Matutes E, Dyer MJS, Mason DY, Catowsky D. mb-1: A new marker for B lineage lymphoblastic leukemia. Blood 1993;82:853–857.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bc1-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83: 5214–5218.
   PubMed Web of Science ®Google Scholar
• Bakshi A, Jensen JP, Goldman P. Cloning the chromosomal break point of t(14:18) human lymphomas. Cell 1985;41: 889–906.
   Google Scholar
• Hockenbery D, Nunez G, Miliman C, Schreiber RD, Korsmeyer SJ. Bc1-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348: 334–336.
   PubMed Web of Science ®Google Scholar
• Hockenbery DM, Oltavi ZN, Yin XM, et al. Bc1-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75: 241–251.
   PubMed Web of Science ®Google Scholar
• Yang S, Korsmeyer SJ. Molecular thanaptosis: A discourse on bc1-2 family and cell death. Blood 1996;88:386–401.
   PubMed Web of Science ®Google Scholar
• Farrow SN, Brown R. New members of the Bc1-2 family and their protein partners. Curr Opin Genet Dev 1996;6:45–49.
   PubMed Web of Science ®Google Scholar
• Tang C, Willingham MC, Reed JC, et al. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 19948:1960-1966.
   PubMed Web of Science ®Google Scholar
• Maung ZT, MacLean FR, Reid MM, et al. The relationship between bc1-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 1994;88: 105–109.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Kitanaka A, Pui CH, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996;87: 1140–1146.
   PubMed Web of Science ®Google Scholar
• Gala JL, Vermylen C, Cornu G, et al. High expression of bc1-2 is the rule in acute lymphoblastic leukemia, except in Burkitt’s subtype at presentation, and is not correlated with the prognosis. Ann Hematol 1994;69:17–24.
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, et al. A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18–24.
   PubMed Web of Science ®Google Scholar
• Campos L, Sabido O, Sebban C, et al. Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 1996;10:434–438.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Yang ZW, Sather H, et al. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed child-hood acute lymphoblastic leukemia: A children’s cancer group study. Blood 1997;89:3769–3777.
   PubMed Web of Science ®Google Scholar
• Sriniwas G, Kusumkumari P, Nair MK, Paniker KR, Pillai MR. Mutant p53 protein, bc1-2/bax ratios and apoptosis in pediatric acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2000;126: 62–67.
   PubMed Web of Science ®Google Scholar
• Wolowiec D, Mekki Y, Ffrench P, et al. Differential expression of cell proliferation regulatory proteins in B- and T-lineage acute lymphoblastic leukaemias. Br J Haematol 1996;95: 518–523.
   PubMed Web of Science ®Google Scholar
• Salomons GS, Brady HJM, Venvijs-Janssen M, et al. The Bax: Bc1-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int j Cancer 1997;71: 959–965.
   PubMed Web of Science ®Google Scholar
• Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999;93:2671–2678.
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, Korsmeyer Sj. BcI-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993;74: 609–619.
   PubMed Web of Science ®Google Scholar
• Yin X-M, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bc1-2 are required for inhibition of apoptosis and hetero-dimerization with Bax. Nature 1994;369: 321–323.
   PubMed Web of Science ®Google Scholar
• Stoetzer OJ, Missler V, Darsow M, et al. Association of bc1-2, bax, bcI-xL and inteuleukin-1 converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996;10:S18.
   PubMed Web of Science ®Google Scholar
• Pepper C, Hoy T, Bentley DP. Bc1-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76: 935–938.
   Web of Science ®Google Scholar
• Binder C, Marx D, Binder L, Schauer A, Hiddemann W. Expression of Bax in relation to Bc1-2 and other predictive parameters in breast cancer. Ann Oncol 1996;7: 129–133.
   PubMed Web of Science ®Google Scholar
• Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated genes bax and bc1-2 in ovarian cancer. Anticancer Res 1997;17:2233–2241.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990;75: 174–179.
   PubMed Web of Science ®Google Scholar
• Meijerink JPP, Mensink EJBM, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998;91:2991–2997.
   PubMed Web of Science ®Google Scholar